This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Bio-Rad
other brands :
Biogenesis, Serotec, AbD Serotec, Oxford Biotechnology
product type :
antibody
product name :
MOUSE ANTI HUMAN RRM2:Preservative Free
catalog :
MCA3434Z
quantity :
0.1 mg
price :
547 USD
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
1E1
reactivity :
human, mouse
application :
western blot, immunocytochemistry
citations: 1
Published Application/Species/Sample/DilutionReference
  • western blot; mouse
  • western blot; human
Kerr M, Scott H, Groselj B, Stratford M, Karaszi K, Sharma N, et al. Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer. Clin Cancer Res. 2014;20:5435-45 pubmed publisher
product information
EntityType :
Monoclonal Antibody
EntityCategory :
Antibodies
ProductCode :
MCA3434Z
Description :
MOUSE ANTI HUMAN RRM2:Preservative Free
Specificity :
RRM2
TargetSpecies :
Human
Host :
Mouse
Format :
Preservative Free
Isotypes :
IgG1
Applications :
IF,WB,P*
ApplicationTypes :
Western Blotting,Immunohistology - Paraffin,Immunofluorescence
CrossReactivities :
Rat
Clone :
1E1
Quantity :
0.1 mg
QuantityValue :
0.1
QuantityType :
mg
GOAccessions :
GO:0046914,GO:0015949,GO:0009263,GO:0055114,GO:0009186,GO:0004748,GO:0000083,GO:0005829,GO:0006260
GOTerms :
GO:0055133,G1/S-specific transcription in mitotic cell cycle,regulation of transcription from RNA polymerase II promoter of G1/S-phase of mitotic cell cycle,regulation of transcription involved in G1/S-phase of mitotic cell cycle,2'-deoxyribonucleoside-diphosphate:oxidized-thioredoxin 2'-oxidoreductase activity,2'-deoxyribonucleoside-diphosphate:thioredoxin-disulfide 2'-oxidoreductase activity,adenosylcobalamin-dependent ribonucleotide reductase activity,aerobic non-heme iron-dependent ribonucleotide reductase activity,anaerobic iron-sulfur-dependent ribonucleotide reductase activity,class I ribonucleotide reductase activity,class II ribonucleoside-diphosphate reductase activity,class II ribonucleotide reductase activity,class III ribonucleotide reductase activity,GO:0016959,GO:0016960,GO:0016961,nucleoside diphosphate reductase activity,purine/pyrimidine nucleoside diphosphate reduction,ribonucleoside 5'-diphosphate reductase activity,ribonucleoside diphosphate reductase activity,ribonucleotide diphosphate reductase activity,ribonucleotide reductase activity,RNR,oxidation reduction,oxidoreductase process,deoxyribonucleoside diphosphate metabolism,deoxyribonucleotide anabolism,deoxyribonucleotide biosynthesis,deoxyribonucleotide formation,deoxyribonucleotide synthesis
UniprotAccessions :
P31350
Gene :
RRM2
GeneID URL :
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=6241
EntityFormats :
Preservative Free
UNSPSC :
41116161
Concentration :
Ig concentration 0.5 mg/ml
ProductForm :
Purified IgG - liquid
PriceGBP :
391
PriceEUR :
547
PriceUSD :
547 USD
PriceCHF :
596.23
PriceSEK :
5749
PriceNOK :
5858
PriceDKK :
4081
company information
Bio-Rad
Endeavour House, Langford Business Park
Langford Lane, Kidlington
OXON, OX5 1GE
antibody_sales_uk@bio-rad.com
https://www.bio-rad-antibodies.com
1 800 265 7376 (North America)
44 (0)1865 852 700 (Rest of World)
headquarters: UK
Bio-Rad is one of the world's leading antibody manufacturers, offering over 12,000 antibodies and related reagents for a focused range of research areas such as immunology, cancer, veterinary research and cell biology through its antibody experts formerly known as AbD Serotec.
The range includes apoptosis kits, autophagy reagents, CD markers, epitope tag antibodies, immunology antibodies, neuroscience antibodies, and veterinary reagents.
Bio-Rad has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as ISO 9001 certified facilities in Germany and the United States.
Our expertise extends to traditional and recombinant antibody generation and production services. Our custom generation service delivers antibodies in as little as 8 weeks with greater than 90% success. The in vitro technology enables selection of antibodies to challenging targets, long term consistent supply, and provision of the antibody sequence.
At Bio-Rad we are committed to your success when using our antibodies and we focus on providing the technology, products and all the supporting information you need to excel in your research.